A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the antiviral efficacy of Boceprevir-based therapy
for the treatment of genotype 6 chronic hepatitis C infection.
Boceprevir has recently been approved for the treatment of genotype 1 chronic hepatitis C
infection. Recent in vitro studies suggest similar efficacy against genotype 6 chronic
hepatitis C infection.
The investigators therefore hypothesise that:
i) Boceprevir is a potent inhibitor of genotype 6 hepatitis C replication in vivo.
ii) Boceprevir in combination with pegylated interferon-alpha and ribavirin for 24 weeks will
cure a high proportion of patients chronically infected with genotype 6 chronic hepatitis C
infection.